# US 2017/0253554 A1 · Cyclopropanecarboxylic acid gpr120 modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253554 A1
- Document ID: US20170253554A1
- Status: Published application
- Kind: A1
- Application number: 15/509,214
- Filed: 2015-09-08
- Published: 2017-09-07
- Earliest claimed: 2014-09-09
- Assignees: Bristol-Myers Squibb Company
- Applicants: Bristol-Myers Squibb Company
- Inventors: Yan Shi; Peter T.W. Cheng; Ying Wang; Sutjano Jusuf; Shiwei Tao; Hao Zhang; Shung C. Wu; Jeffrey A. Robl
- Web page: https://patentgrep.com/patent/US20170253554A1

## CPC

- C07C 62/34: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/415: 1,2-Diazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 31/4418: having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- C07C 59/64: containing six-membered aromatic rings
- C07D 207/323: with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atoms
- C07D 213/55: Acids; Esters
- C07D 213/65: attached in position 3 or 5
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 277/593: Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
- C07D 307/79: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D 307/82: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07C 2601/02: with a three-membered ring
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein coupled receptor modulators which may be used as medicaments

## Claims

### Claim 1

The compound of the formula
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof, wherein:
R1 is independently selected from: phenyl and a 5- to 6-membered heteroaryl comprising carbon atoms and 1-4 heteroatoms selected from N, NRb, O, and S(O)p; wherein said phenyl and heteroaryl are substituted with 0-4 R5;
L1 is independently —CH2CH2—, —CH2OCH2—, —CH2O— or —OCH2—;
L2 is independently a bond or —CH2—;
R2, at each occurrence, is independently selected from: halogen, C1-6 alkyl substituted with 0-1 Ra, C1-4 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, and C1-4 haloalkoxy;
R3 and R4, at each occurrence, are independently selected from the group consisting of H, halogen, C1-4 alkyl, C1-4 alkoxy, and C1-4 haloalkyl;
R5 at each occurrence, is independently selected from: halogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, C1-6 haloalkyl, C1-6 haloalkoxy, —O—C2-6 alkenyl, SO2(C1-4 alkyl), and —(O)0-1—(CH2)0-2—R6;
alternatively, two R5 groups, when they are attached to two adjacent carbon atoms and together with the carbon atoms to which they are attached, combine to form a 5- to 6-membered carbocyclic or heterocyclic ring comprising carbon atoms and 0-3 heteroatoms selected from N, NRb, O, and S(O)p; wherein said heterocycle is substituted with 0-2 Rc;
R6 is independently selected from: C3-6 carbocycle and a 5- to 6-membered heterocycle comprising carbon atoms and 1-4 heteroatoms selected from N, NRb, O, and S; wherein said carbocycle and heterocycle are substituted with 0-3 Rc;
Ra, at each occurrence, is independently selected from: C1-4 alkoxy and C(═O)H;
Rb, at each occurrence, is independently selected from: H, C1-4 alkyl, and —(CH2)0-2-phenyl;
Rc, at each occurrence, is independently selected from: halogen, C1-6 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, CO2(C1-4 alkyl), and COPh;
m is independently 0, 1, or 2; and
p is, independently at each occurrence, selected from 0, 1, and 2.

### Claim 2 (depends on 1)

A compound according to claim 1 of Formula (IIa), (IIb), (IIc), (IId) or (IIe):
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof,

### Claim 3 (depends on 2)

A compound according to claim 2
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof,
wherein:
R2 is independently selected from: halogen and C1-4 alkyl;
R3 is independently H or halogen;
R4 is independently H or C1-4 alkyl; and
m is independently 0 or 1.

### Claim 4 (depends on 3)

A compound according to claim 3
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof,
wherein:
R1 is independently selected from: phenyl substituted with 0-3 R5, pyridyl substituted with 0-2 R5, thiazolyl substituted with 0-2 R5,
R5 at each occurrence, is independently selected from: halogen, C1-6 alkyl, C1-6 alkoxy, C1-4 alkylthio, C1-4 haloalkyl, C1-4 haloalkoxy, —O—C2-6 alkenyl, —O(C3-6 cycloalkyl), —OCH2(C3-6 cycloalkyl), —(O)0-1-(phenyl substituted with 0-2 Rc), and —(O)0-1-(pyridyl substituted with 0-2 Rc).

### Claim 5 (depends on 4)

A compound according to claim 4
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof,
wherein:
R3 is independently H or F; and
R4 is independently H or Me.

### Claim 6 (depends on 5)

A compound according to claim 5
or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof,
wherein:
R3 and R4 are H.

### Claim 7 (depends on 1)

A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and a compound of claim 1, or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

The pharmaceutical composition according to claim 7, further comprising one or more other suitable therapeutic agents useful in the treatment of the aforementioned disorders including: anti-diabetic agents, anti-hyperglycemic agents, anti-hyperinsulinemic agents, anti-retinopathic agents, anti-neuropathic agents, anti-nephropathic agents, anti-atherosclerotic agents, anti-ischemic agents, anti-hypertensive agents, anti-obesity agents, anti-dyslipidemic agents, anti-hyperlipidemic agents, anti-hypertriglyceridemic agents, anti-hypercholesterolemic agents, anti-pancreatitis agents, lipid lowering agents, anorectic agents and appetite suppressants.

### Claim 9 (depends on 7)

The pharmaceutical composition according to claim 7, further comprising one or more other suitable therapeutic agents selected from: a dipeptidyl peptidase-IV inhibitor, a sodium-glucose transporter-2 inhibitor and a 11b-HSD-1 inhibitor.

### Claim 10 (depends on 1)

The compound of claim 1 for use in treating diabetes, hyperglycemia, impaired glucose tolerance, gestational diabetes, insulin resistance, hyperinsulinemia, retinopathy, neuropathy, nephropathy, diabetic kidney disease, acute kidney injury, cardiorenal syndrome, delayed wound healing, atherosclerosis and its sequelae, abnormal heart function, congestive heart failure, myocardial ischemia, stroke, Metabolic Syndrome, hypertension, obesity, fatty liver disease, dislipidemia, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low high-density lipoprotein (HDL), high low-density lipoprotein (LDL), lipid disorders and liver diseases such as NASH (Non-Alcoholic SteatoHepatitis), NAFLD (Non-Alcoholic Fatty Liver Disease) and liver cirrhosis.

### Claim 11 (depends on 1, 10)

A compound for use according to claim 10, wherein the compound of claim 1 is used simultaneously, separately or sequentially with one or more additional therapeutic agents.
